Central Nervous System (CNS)

Perceptive has spent 20 years specializing in neuroscience imaging solutions for preclinical, early-phase, and late-phase clinical studies.

Person pointing at musculoskeletal image scan on computer screen with a ballpoint pen

Overview

Our capabilities span from in vitro assays to in vivo imaging using PET, SPECT, and MRI imaging biomarkers in CNS drug development and CNS clinical trials. We have expertise in coordinating worldwide multi-center imaging studies and providing management and oversight of radiotracer supply for both commercial and non-commercially available agents.

Solutions include:

Preclinical Imaging
Phase 0-IV Imaging Support
Clinical Imaging Core Lab
Advanced Image Analytics Including Novel IQ Analytics Suite
Quantitative Imaging Endpoints

Imaging-Services_Scientific-Regulatory-Expertise

CNS Expertise

Invicro has industry leading operational oversight and extensive experience with preclinical, early phase (single-site) and late phase (multi-center) trials. This enables us to provide sponsors with unparalleled support and guidance to ensure successful study execution.

- 430+ clinical CNS imaging trials managed
  - >200 AD and PD Studies with >56,000 subjects imaged
- 90+ Phase I & II, multi-center trials conducted with PET and MRI
- 2100+ imaging centers qualified worldwide
- Two “in-house” clinical imaging centers
- Development and application of 140+ novel neuro imaging agents
- Redefining imaging analytic techniques
  - Amyloid, Tau and Dat IQ analytics
  - SUVR analysis
  - Centiloid analysis

Solutions

Preclinical

Perceptive has many years of experience supporting preclinical CNS drug discovery and development programs. Our tissue biomarker services along with our functional and molecular imaging solutions are well-suited for non-invasive longitudinal studies to provide multiple readouts, such as biodistribution, target-occupancy relationships and therapeutic efficacy.

Biodistribution
Target Engagement & Occupancy Studies
Neuropharmacodynamics
Neurotransmitter Release
Biological Therapeutics Pharmacokinetics
Neuroinflammation
Neuromodulator Analysis

Early-Phase Clinical

We support a wide range of first-in-human, pre-proof of concept CNS clinical trial imaging studies spanning phases I-IIa.

MRI

Brain volumetric analysis
Changes in brain activity and cerebral blood flow
Tissue microstructure
Tissue susceptibility
Pharmacodynamic responses

PET

Radioligand dosimetry
Quantitative drug brain distribution
Target engagement
Drug concentration – Target occupancy relationship
Pharmacodynamic responses

Late-Phase Clinical

Perceptive’s Late Phase (IIb-IV) CNS clinical trial imaging capabilities enable the execution and delivery of large-scale clinical trials for diagnosis, progression, and disease monitoring through optimized study design, world-wide imaging site set up, iPACs driven data management and quantitative analytics. This end-to-end service is deployed in the necessary regulatory infrastructure to deliver clinical trial results ready for regulatory filing.

Core lab capabilities with complete project support
Clinical imaging center evaluation, selection, set up, training and management
Rapid analysis for study eligibility
Quantitative analysis for monitoring drug effect
Image data management and regulatory compliance services

Advanced Image Analytics

We develop advanced algorithms and pipelines to solve complex image science problems, including the use of machine learning and deep learning techniques. These methods are built on our deep scientific domain knowledge to deliver optimal analytical performance and relevant biological outcome measures for a variety of tasks, including:

IQ Analytics Suite – Tau, Amyloid and DaT Imaging
Batch Image Triage & QC
Tracer Kinetic Analysis
Biomathematical Modeling
Image Registration, Segmentation and Volumetric Analysis
Radiation Dosimetry

Learn about Perceptive's extensive imaging experience and capabilities:

Oncology

Bringing new cancer therapies to the market is a complex and challenging process that requires a partner who can support you every step of the way.

Learn more

Radioligand Therapy

Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor-targeting small molecules, peptides, or biologics to deliver a cytotoxic payload that induces DNA damage in tumor cells while limiting damage to normal and healthy tissue.